Is The Market Wrong About Bristol-Myers Squibb?

Published: Jun 16, 2017

Bristol-Myers Squibb (BMS) (NYSE:BMY) might be the pharmaceutical company equivalent of the late comedian Rodney Dangerfield. Dangerfield's money-line during his career was, "I don't get no respect." BMS executives and shareholders could be saying the same thing these days. The stock is down nearly 30% after disappointing clinical study results for cancer drug Opdivo were announced in August 2016.

Back to news